Eicosapentaenoic Acid for Cardiovascular Events Reduction — Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

This network meta-analysis lands a pointed, contrarian question on the omega-3 debate: was EPA’s celebrated benefit real, or an artifact of the placebo it was tested against?

Pooling 17 trials and a remarkable 141,000 participants, the authors found that EPA reduced cardiovascular death, heart attack, and stroke only when compared with mineral oil — the placebo used in the landmark REDUCE-IT trial — and not when compared with other oils or controls. If mineral oil is not inert but mildly harmful, then some of EPA’s apparent advantage may reflect a worse comparator rather than a better drug.

The practical takeaway is interpretive caution: the strength of the EPA-only case may be overstated, and the choice of placebo in these trials matters more than usually acknowledged. The status-quo friction is direct — it challenges the marketing of EPA-only products and the reading of REDUCE-IT.

We rate the evidence moderate-to-solid: a large, methodologically careful network meta-analysis, limited by trial heterogeneity and the very placebo-confounding it spotlights. Its clinical significance is meaningful — it injects necessary doubt into a field prone to overclaiming, and pairs instructively with the EPA-favoring reviews elsewhere in this library (Nelson, Brinton & Mason, Khan) as the skeptical counterweight.